Monrovia's Xencor reports disappointing third-quarter financial results.
The company says: "Revenues for the third quarter ended September 30, 2014 were $0.8 million, compared to $3.2 million in the same period of 2013. Revenues for the nine month period ended September 30, 2014 were $3.9 million, compared to $8.4 million for the same period in 2013."
It says it "expects to have sufficient cash to fund research and development programs and operations through 2016."
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer.
- Brad Haugaard
No comments:
Post a Comment